Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Xenon Pharmaceuticals Inc. (XENE) had Return on Tangible Equity of -13.36% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-84.71M |
|
-- |
|
-- |
|
$94.23M |
|
$-94.23M |
|
$8.90M |
|
$-85.33M |
|
$-85.33M |
|
$-84.71M |
|
$-84.71M |
|
$-84.71M |
|
$-84.71M |
|
$-94.23M |
|
$-93.60M |
|
78.95M |
|
78.95M |
|
$-1.07 |
|
$-1.07 |
|
| Balance Sheet Financials | |
$500.25M |
|
$9.21M |
|
$174.03M |
|
$674.28M |
|
$33.05M |
|
-- |
|
$7.26M |
|
$40.30M |
|
$633.98M |
|
$633.98M |
|
$633.98M |
|
76.94M |
|
| Cash Flow Statement Financials | |
$-125.89M |
|
$116.77M |
|
$1.22M |
|
$142.71M |
|
$135.38M |
|
$-7.33M |
|
$25.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-126.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.36% |
|
|
Return on Tangible Equity |
-13.36% |
-12.56% |
|
-13.36% |
|
$8.24 |
|
$-1.60 |
|
$-1.59 |
|